Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical...
May 16 2018 - 5:00PM
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
therapy to treat cancer, will release updated data from ongoing
clinical studies at the annual ASCO meeting at McCormick Place in
Chicago, Illinois.
Data from the ongoing pilot study of NY-ESO SPEAR T-cells in
myxoid/round cell liposarcoma (MRCLS) will be presented during an
oral presentation by Dr. Sandra P. D’Angelo of
the Memorial Sloan Kettering Cancer Center. GlaxoSmithKline
plc (LSE:GSK) (NYSE:GSK) exercised its option to exclusively
license the right to research, develop, and commercialize NY‑ESO
SPEAR T-cell therapy program in September 2017. Transition of
this program to GSK is ongoing.
In addition, data from Adaptimmune’s ongoing MAGE‑A10 pilot
studies will be presented at a poster session.
Oral presentation of updated MRCLS data:
- Title: Pilot Study of NY-ESO-1c259T Cells in
Advanced Myxoid/Round Cell Liposarcoma
- Abstract #: 3005
- Oral session: Developmental
Therapeutics—Immunotherapy
- Date: Saturday June 2, 2018
- Time: 4:24 PM – 4:36PM (CDT)
- Location: McCormick Place South, Hall B1
Poster presenting MAGE-A10 safety data
- Title: Initial safety assessment of
MAGE-A10c796TCR T-cells in two clinical trials
- Abstract #: 3056
- Poster session: Developmental
Therapeutics—Immunotherapy
- Date: Monday June 4, 2018
- Time: 8:00 AM-11:30 AM (CDT)
- Location: McCormick Place South, Hall A
About AdaptimmuneAdaptimmune is a
clinical-stage biopharmaceutical company focused on the development
of novel cancer immunotherapy products. The Company’s unique SPEAR
(Specific Peptide Enhanced Affinity Receptor) T‑cell platform
enables the engineering of T-cells to target and destroy cancer,
including solid tumors. Adaptimmune is currently conducting
clinical trials with SPEAR T-cells targeting MAGE-A4, -A10, and AFP
across several solid tumor indications. GlaxoSmithKline
plc (LSE:GSK) (NYSE:GSK) exercised its option to exclusively
license the right to research, develop, and commercialize
Adaptimmune’s NY-ESO SPEAR T-cell therapy program in September
2017. Transition of this program to GSK is ongoing. The
Company is located in Philadelphia, USA and Oxfordshire, U.K. For
more information, please visit http://www.adaptimmune.com
Forward-Looking StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Quarterly Report filed
on form 10-Q with the Securities and Exchange Commission (SEC) on
May 9, 2018 and our other SEC filings. The forward-looking
statements contained in this press release speak only as of the
date the statements were made and we do not undertake any
obligation to update such forward‑looking statements to reflect
subsequent events or circumstances.
Adaptimmune Contacts:
Media Relations:Sébastien Desprez – VP,
Communications and Investor RelationsT: +44 1235 430 583M: +44 7718
453 176 Sebastien.Desprez@adaptimmune.com
Investor Relations: Juli P. Miller, Ph.D. –
Director, Investor RelationsT: +1 215 825 9310M: +1 215 460
8920Juli.Miller@adaptimmune.com
GSK (NYSE:GSK)
Historical Stock Chart
From Aug 2024 to Sep 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2023 to Sep 2024